Tag Archives: biotech

Not Seeking Additional Capital? Why you should Keep a Dialogue with Investors Anyways

19 Jul

By Danielle Silva, Director of Research, Life Science Nation

At LSN, I have the pleasure of regularly speaking with entrepreneurs about their startups. One topic that always comes up during these discussions is the subject of fundraising – especially for early stage firms. What often surprises me is that many of these entrepreneurs have the mentality that they do not need to be in dialogue with investors if they are not looking to raise additional capital. Many of these entrepreneurs question why they would “waste” their time going to networking events or conferences if they are not trying to attract investors; instead, they believe their time is better spent further developing their product. Speaking with investors even when you’re not looking to attract capital needs to be part of your business development plan, and is just as valuable as taking time to develop your product.

Picture this scenario: you’re an early stage company that is developing a therapeutic that just received $15 million for their series A financing round (let’s say the $15 million came from three different VCs). So you’re thinking that you have enough capital to, say, get you through the next four years. There’s no need to speak with investors for now, right?

Don’t be so sure – the deal may stipulate that you do not receive all of this money upfront; maybe you only receive capital once you’ve hit certain milestones, let’s say your first milestone you need to achieve a year after the date you signed the term sheet. If, for instance, you only got a small percentage of this capital upfront, the economy slows down, and two of the VCs that invested in you go under because all of their LPs withdrew their capital, the remaining VC may be unable to cover the rest of the money that should have been allocated to your firm. Now your firm is left with way less cash than you thought you would be working with.

Now this is obviously a dramatic example, but the point here is that you never know what the future holds. One of your investors may go under, but a more likely scenario is that you go to a current investor in your firm expecting them to provide you with some additional capital to get you through, and they just don’t have the ability to deliver. Not being able to get supplementary capital from existing investors – or worse, being unable to even get the money promised to you by investors – are two examples of situations your firm could be in where you would certainly be kicking yourself for not keeping dialogue with outside investors.

Another reason to reach out to new investors – especially through networking events and conferences – is to gain feedback on your product or business. If you start a dialogue with an investor asking for feedback on your business, it can be a great way to start a relationship with an investor, and can be a mutually beneficial way to share and learn. You can learn a lot about the general market from speaking with investors, and maybe even get some additional insight on your competitors. Starting a dialogue in this manner can also lead to a relationship with the investor, which could translate into an investment down the road.

So whether you’re a startup who has just raised money, or even a later stage firm who has just received a large injection of capital, speaking and networking with investors needs to be a priority. Your firm needs to have the mentality that you are always fundraising in order to stay in constant dialogue with investors. In short, if you are a firm who has just raised money, the next time an investor calls, or you have the chance to go to an investor networking event or a conference, just say yes.

CROs turning to Private Investors for Deal Flow

19 Jul

By Max Klietmann, VP of Research, LSN

I recently had the opportunity to speak with a CRO business development executive who wanted to know more about the emerging investor categories outside of venture capital that LSN tracks. I asked if his firm was seeking financing, and he told me that they weren’t; like many others in his field, rather, the CRO was seeking strategic sources of future business for his firm. Many service providers in the life sciences are increasingly becoming aware of the critical importance of including investors as a key group in their business development activities on an ongoing basis.

Historically, a few major CROs maintained relationships with the big life science venture firms as a source of business by way of portfolio companies. However, in recent history, as many of the established VCs have ceased to invest early (where it’s easy for a CRO to establish a position with a biotech), this source of business has dried up. Savvy CROs have recognized that in order to maintain a competitive edge, they need to seek out the new categories of investors that have emerged to fill this gap. Strategic partnerships with hedge funds, family offices, foundations, and venture philanthropy groups can all be highly productive sources of CRO deal flow. These organizations all recognize strong CRO partners as a means to help portfolio companies and grant recipients be more capital-efficient by getting product to market faster, so why aren’t CRO’s across the board taking advantage of this opportunity?

Basically, it comes down to a question of finding the right partners and building a relationship. In an industry that is defined by fit, it is critical for service providers to know who is actively investing in companies reflecting their area of expertise. LSN is specialized in sourcing these emerging opportunities, and increasingly, CROs are showing an interest in tracking this information. Forging alliances with the right investors early is the straightest route to sustained future business, and identifying those entities will define the winners (and losers) in the CRO space in the future.

 

Hot Life Science Investor Mandate 1: Eastern US Angel Group Targeting Orphan Indications

19 Jul

An angel group based in the Eastern US currently has around $15 million in total assets under management, and is currently deploying capital from its third fund. The firm is looking for new opportunities in the life science space, but has no set timeline to make allocations. The group typically allocates between $250,000 and $2 million per company.

Currently, the angel group is most interested in the biotech therapeutics and medtech space, but only those that are targeting orphan indications. The group will not consider therapeutics and diagnostics that are treating any other indications besides orphan diseases due to the current difficult FDA regulatory framework.

The group is looking for pre-revenue companies within this area. However, they would consider companies in the biotech therapeutics space that have products in the preclinical stage through phase III of development, and in the medtech space the firm is looking for companies that have a product in development, or have a prototype.

Hot Life Science Investor Mandate 2: Opportunistic PE Seeks CMO for New Allocations

19 Jul

A private equity group based in the Eastern US has around $200 million in assets, and has raised two funds. The firm is currently looking for new opportunities in the life sciences space, and although the firm has no set time frame to make allocations, they are always opportunistically looking to source new investments in the space.

The firm’s typical equity investment size ranges from $10-40 million. Currently, they are most interested in information providers as well as Biotech R&D services firms. In the information provider space, the group is seeking healthcare IT firms, and in the biotech R&D services space, the firm is looking for contract manufacturing organizations (CMOs). The firm solely invests in firms based in North America, and will consider companies headquartered in either the U.S. or Canada.

The firm is looking for companies that have $5-15 million in EBITDA, and $35-100 million in revenue, and $25-125 million in enterprise value, however EBITDA is the most important criteria in terms on the firms investment requirements. Accordingly, the firm does not invest in pre-revenue companies.

Hot Life Science Investor Mandate 3: Venture Arm with Strong Backing Deploying Capital to Healthcare IT

19 Jul

A venture and expansion capital arm of a larger organization based in the Central US has around $300 million in total assets under management, and is currently deploying capital from its third fund, which closed at nearly $200 million. The firm is currently seeking opportunities in the life science sector, and while they have no strict timeline to make investments, they would invest in a new firm within the next 6-9 months if a compelling opportunity were identified. The firm’s equity investments range from $3-10 million, but are typically in the $8-10 million range.

Currently, this firm is most interested in the medtech, biotech diagnostics, and information providers spaces. Specifically, they are looking for healthcare IT firms within the information providers space. The firm is very opportunistic within the areas of biotech diagnostics and medtech, and would be willing to look at companies that fall within the full gamut of the medtech and diagnostics subsectors. The firm, however, will only consider US based firms within the venture and expansion capital space.

The firm is most interested in early stage companies, and is interested in pre-revenue firms. With that being said, they will look at firms that have products that are in-development, or firms that have a prototype of their product, but will not consider firms that have a device that is on the market.

Hot Life Science Investor Mandate 3: Generalist PE Fund Interested in CROs, CMOs

11 Jul

A private equity fund located in the Central US with roughly $1 billion under management intends to make allocations in the tens of millions on a case-by-case basis in 2013. The firm is generalist and invests across sectors, but has a specific interest in life sciences & medical technologies. Within this space, the firm is opportunistic in almost every aspect, but does require that an issuer be EBITDA-positive. This means that a firm must have at least one product on the market generating revenue to be of interest. Though the firm has looked at and invested in therapeutics and medtech companies historically, a primary interest currently is service providers such as CROs and CMOs.

Hot Life Science Investor Mandate 1: NPO Looking for Biotechs Developing Brain Disorder Therapeutics

11 Jul

A non-profit based in the Western US with nearly $50 million in assets is interested in biotech firms developing therapeutics that target brain disorders. The firm typically allocates from the hundreds of thousands into the millions per firm, and is looking to allocate to one more firm in the life science’s space for their second fund. They are especially interested in technologies that are able to deliver therapeutics across the blood brain barrier, as well as the personalized medicine space. The firm prefers funds that are in between phase I and phase II of the clinical development process, but will consider products in preclinical, phase I, and phase II development.